July 9, 2021 5:41pm

However, earnings or LPS (loss-per-share) season is just around the corner

The Biostage (BSTG) Chronicles: BSTG is trying to execute the remaining $2.00 very private placement warrants and add yet another layer of unregistered stock. Friday, 1060 shares traded with no upside (-$0.00 to $1.50)

Pre-open indications: 1 HIT

Week in review … bluebird bio (BLUE) has positive news and only advances +$0.14 to $30.57

My comments try to distinguish the temporary from real pricing digression or progress.

It takes courage to not be discouraged by sector volatility!

The Dow closed UP +448.23 points (+1.30%); the S&P closed UP +48.73 points (+1.13%) while the Nasdaq closed UP +142.13 points (+0.98)

 

Henry’omics:

Indexes notched record closes on Friday, rebounding from the previous session’s losses over concerns of a slowdown in global economic growth.

  • For the week. The Dow rose 0.25%, the S&P 500 gained +0.4% and Nasdaq expanded 0.4%.

 

RegMed Investors’ (RMi) pre-open: “Christmas in July or is there no gas for the grill? We should be enjoying this season of grilling even under the clouds of rain beneath the patio umbrella; instead, I’m “bitchin” about the cell and gene therapy sector and markets” …  https://www.regmedinvestors.com/articles/11991

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Friday opened negative at 15/18, 1 flat and 1 acquired, popped positive at the mid-day to 27/6, 2 flats and 1 acquired, closing positive 27/6, 1 flat and 1 acquired;
  • Thursday opened negative at 2/31, 1 flat and 1 acquired, jumped positive at the mid-day to 20/14 and 1 acquired, closing barely positive 17/16, 1 flat and 1 acquired;
  • Wednesday opened negative at 4/30, 1 flat and 1 acquired, stayed negative at the mid-day to 9/25 and 1 acquired, closing negative 8/25, 1 flat and 1 acquired;
  • Tuesday opened negative at 1/30, 3 flats and 1 acquired, stayed negative at the mid-day to 7/27 and 1 acquired, closing negative 7/26, 1 flat and 1 acquired;
  • Monday was a holiday,

 

The Biostage (BSTG) Chronicles: The “pump” is STILL promoting on Friday as 1060 shares traded with the share price closing FLAT after Thursday with 210 shares traded after Wednesday with 15,903 shares traded to “push/promote” the exercise of warrants to add more unregistered shares to the “outstanding” … WHO and WHOM are trading – as if we didn’t know?

 

News: bluebird bio (BLUE +$0.14) the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable.

  • BLUE has informed the EMA that the company is lifting the voluntary marketing suspension.

 

Pre-open Indications: 1 HIT << Maintaining SELL: Biostage (BSTG -$0.00) and 0 MISS

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), Fate Therapeutics (FATE), Editas Medicine (EDIT), Cellectis SA (CLLS), BioLife Solutions (BLFS) to name 5 of the 27 inclining of the 35

Hammered in today’s market:

  • ReNeuron (RENE.L) – another, again; Vericel (VCEL)-again; Ultragenyx (RARE), CRISPR Therapeutics (CRSP), Regenxbio (RGNX), Solid Biosciences (SLDB) to name 6 of the 6 declining of the 35 covered

 

Key Metrics:

  • Sector volume was LOW with 3 of the 27-upside having higher than the 3-month average volume with NADA volume of 0 of 6-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 27-upside were +0.18% (NTLA) to +9.28% (CLLS) while the 6-downside ranges from -0.33% (CRSP) to -2.78% (VCEL);

 

Friday’s (10 of 27) incliners:

  • Alnylam Pharmaceuticals (ALNY +$4.24);
  • Fate Therapeutics (FATE +$3.24 after Thursday’s +$0.90, Wednesday’s -$1.08 and Tuesday’s -$5.41);
  • Editas Medicine (EDIT +$2.35 after Thursday +$0.52, Wednesday’s -$2.44 and Tuesday’s -$6.76);
  • Cellectis SA (CLLS +$1.34);
  • Global Blood Therapeutics (GBT +$0.77 after Thursday’s +$0.63, Wednesday’s +$0.06 and Tuesday’s -$0.95);
  • uniQure NV (QURE +$0.76 after Thursday’s -$0.41, Wednesday’s -$0.98 and Tuesday’s -$1.06);
  • Intellia Therapeutics (NTLA +$0.27 after Thursday’s +$7.71, Wednesday’s -$4.43 and Tuesday’s -$14.26);
  • Chinook Therapeutics (KDNY +$0.26 after Thursday’s +$0.43 and Wednesday’s +$0.30);
  • Mesoblast (MESO +$0.25);
  • Sage Therapeutics (SAGE +$0.24 after Thursday’s -$0.18, Wednesday’s +$0.01 and Tuesday’s -$1.39);

Friday’s (6 of 6) decliners:

  • ReNeuron (RENE.L -$2.50 after Thursday’s -$2.00, Wednesday’s -$2.50 and Tuesday’s flat);
  • Ultragenyx (RARE -$1.56 after Thursday’s +$3.27, Wednesday’s -$1.79 and Tuesday’s -$2.79);
  • Vericel (VCEL -$1.52 after Thursday’s -$0.02, Wednesday’s +$1.55 and Tuesday’s +$2.78);
  • CRISPR Therapeutics (CRSP -$0.48 after Thursday’s +$2.52, Wednesday’s +$5.81 and Tuesday’s -$7.78);
  • Regenxbio (RGNX -$0.13 after Thursday’s +$0.35, Wednesday’s -$0.80 and Tuesday’s -$1.30);
  • Solid Biosciences (SLDB -$0.07);

Closing 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed up +0.20% and XBI closed up +0.48%
  • Thursday, the IBB closed up +0.20% and XBI closed up +0.48%
  • Wednesday, the IBB closed down -0.88% and XBI closed down -1.68%
  • Tuesday, the IBB closed down -1.14% and XBI closed down -2.15%

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -2.82 points or -14.84% at 16.18
  • Thursday was up +2.80 points or +17.28% at 19
  • Wednesday was down -0.24 points or -1.46% at 16.20
  • Tuesday was up +1.37 points or +9.09% at 16.44

 

Upside volume:

Friday: 3 out of the 27-upside had higher than the 3-month average volume;

Thursday: 1 out of the 17-upside had higher than the 3-month average volume;

Wednesday: 3 out of the 8-upside had higher than the 3-month average volume;

Tuesday: 1 out of the 7-upside had higher than the 3-month average volume;

 

Downside volume:

Friday: 0 out of the 6-downside had higher than the 3-month average volume;

Thursday: 4 out of the 16-downside had higher than the 3-month average volume;

Wednesday: 4 out of the 25-downside had higher than the 3-month average volume;

Tuesday: 5 out of the 26-downside had higher than the 3-month average volume;

 

Percentage (%) movement/range statistics: price versus percentage …

Friday’s percentage (%) of the 27-upside were +0.18% (NTLA) to +9.28% (CLLS) while the 6-downside ranges from -0.33% (CRSP) to -2.78% (VCEL);

Thursday’s percentage (%) of the 17-upside were +0.66% (MESO) to +18.11% (BSTG) while the 16-downside ranges from -0.05% (ALNY) to -6.21% (MDXG);

Wednesday’s percentage (%) of the 8-upside were +0.02% (SAGE) to +2.87% (VCEL) while the 25-downside ranges from -0.19% (AXGN) to -15.33% (BSTG);

Tuesday’s percentage (%) of the 7-upside were +0.51% (VSTM) to +11.11% (BSTG) while the 26-downside ranges from -0.65% (CLBS) to -12.31% (EDIT);

 

July, first month of Q3/21:

Friday closed positive with 27 advancers, 6 decliners, 1 flat and 1 acquired

Thursday closed barely positive with 17 advancers, 16 decliners, 1 flat and 1 acquired

Wednesday closed negative with 8 advancers, 25 decliners, 1 flat and 1 acquired

Tuesday closed negative with 7 advancers, 26 decliners, 1 flat and 1 acquired

Friday closed negative with 9 advancers, 24 decliners, 1 flat and 1 acquired

Thursday (7/1) closed positive with 25 advancers, 8 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE:  Back on the roller-coaster … at least it was a fast and good ride!

I expect smaller and choppier gains, brace for more volatility.

Next few months – unless, news of clinical results or an M&A after a choppy and marginal performance in the first half.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

July starts on a positive note, and be careful of a long, hot, volatile summer.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.